Pegylated liposomal doxorubicin Clinical Trials

5 actively recruiting trials across 3 locations

No change since May 2026

Also known as: Caelyx, Doxil, Lipodox, PLD

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

Yonsei University1
Verastem, Inc.1
Merck Sharp & Dohme LLC1
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc1
InxMed (Shanghai) Co., Ltd.1

Indications

Cancer5
Ovarian Cancer Recurrent2
Low-Grade Serous Ovarian Cancer1
Clear Cell Carcinoma1
Vagina Neoplasm1

Other2 trials

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Phase 2

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Phase 2

Phoenix, Arizona1 trial

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

HonorHealth

Phase 3

Aurora, Colorado1 trial

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Site 0264

Phase 1

Louisville, Kentucky1 trial

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

The University of Louisville, James Graham Brown Cancer Center ( Site 0009)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.